Skip to content

In the BioHarmony Drug Report Database

Niraparib

Zejula (niraparib) is a small molecule pharmaceutical. Niraparib was first approved as Zejula on 2017-03-27. It is used to treat fallopian tube neoplasms, ovarian neoplasms, and peritoneal neoplasms in the USA. It has been approved in Europe to treat fallopian tube neoplasms, ovarian neoplasms, and peritoneal neoplasms. The pharmaceutical is active against poly [ADP-ribose] polymerase 1 and poly [ADP-ribose] polymerase 2. Zejula's patents are valid until 2038-03-27 (FDA).
Trade Name Zejula
Common Name Niraparib
Indication fallopian tube neoplasms, ovarian neoplasms, peritoneal neoplasms
Drug Class Poly-ADP-ribose polymerase inhibitors
Niraparib
Get full access now